- Stocks
- Pharma & Healthcare
- Evoq Remedies
Evoq Remedies share price
NSE: EVOQPharma & HealthcareMedical Distribution
Evoq Remedies at a glance
With a market capitalisation of ₹6 Cr, it ranks 4045th by market cap among the 4,183 NSE companies Pivot tracks (a small-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Medical Distribution.
Its return on equity was 0.2% in FY25. Promoters held 0.02% of the company as of 31 Mar 2026.
Key numbers
- Market cap
- ₹6 CrRank 4045 on NSE
- Price to book
- 0.14×FY25
- ROE
- 0.2%FY25
- ROCE
- 0.3%FY25
- Debt to equity
- 0FY25
- Net profit margin
- 0.8%FY25
- Book value / share
- ₹17.89FY25
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | — | — | — | — | — |
Evoq Remedies financials
| Item | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Revenue | ₹17 Cr | ₹20 Cr | ₹4 Cr | ₹12 Cr |
| Operating profit | ₹1 Cr | ₹2 Cr | ₹1 Cr | ₹0 Cr |
| Net profit | ₹1 Cr | ₹2 Cr | ₹0 Cr | ₹0 Cr |
| EPS (₹) | ₹1.09 | ₹1.19 | ₹0.03 | ₹0.04 |
| Cash from operations | −₹28 Cr | −₹4 Cr | ₹5 Cr | −₹15 Cr |
| Total debt | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Shareholders' equity | ₹23 Cr | ₹25 Cr | ₹25 Cr | ₹45 Cr |
Evoq Remedies shareholding pattern
| Holder | 31 Mar 2024 | 22 Jun 2024 | 30 Sep 2024 | 31 Mar 2025 | 30 Sep 2025 | 31 Mar 2026 |
|---|---|---|---|---|---|---|
| Promoters | 20.53% | 11.21% | 11.21% | 11.21% | 11.21% | 0.02% |
| Non-institutions | 79.47% | 88.79% | 88.79% | 88.79% | 88.79% | 99.98% |
Evoq Remedies vs peers
The listed Pharma & Healthcare companies nearest to Evoq Remedies by market capitalisation.
Ask anything about Evoq Remedies
Pivot answers on the live chart with evidence you can check, and tests strategies against EVOQ's own history. Try: “Why has EVOQ moved over the last three months?” · “Backtest a 50-day moving-average crossover on EVOQ over five years” · “Compare EVOQ with TRINITYLEA on margins and valuation”
Frequently asked questions about Evoq Remedies
What is the market cap of Evoq Remedies?
Evoq Remedies' market capitalisation is ₹6 Cr (₹6 Cr) at the 22 Oct 2026 close, ranking 4045th among the NSE companies Pivot tracks.
What is the ROE and ROCE of Evoq Remedies?
Return on equity was 0.2% in FY25 and return on capital employed was 0.3% in FY25 (standalone figures).
Is Evoq Remedies a debt-free company?
Evoq Remedies is close to debt-free: its debt-to-equity ratio was 0 in FY25.
What is the shareholding pattern of Evoq Remedies?
As of 31 Mar 2026: promoters 0.02%, non-institutions 99.98%.
Who are Evoq Remedies' competitors?
The listed Pharma & Healthcare companies closest to Evoq Remedies by market cap are Trinity League, Adline Chem Lab, Unjha Formula, Dr Lalchandani, Vivanza Bio and DECIPHER LABS.
Is Evoq Remedies a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Evoq Remedies' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on EVOQ against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with E · all NSE stocks · this page as text